Conference call and roadside information on Thursday, August 6 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) Domestic: 877-705-6003 (national)
International: 201-493-6725
Conference ID: 13705182
You can also have a repeat call until August 13. Participants can access the replay from the Investors segment of the company’s website in www.pfenex.com or https://public.viavid.com/index.php? id s 140248.
About Pfenex Inc.
Pfenex is a biogeneration progression apple and license whose advertising products aim to take advantage of its patented form of protein production, Pfenex Expression Technology®, to expand the new generation protein remedies and new to concrete existing remedies and create new remedies for applicable biological objectives with critical ailments are still hoping to be successful to be treated better friend. Using the patented form Pfenex Expression Technology, Pfenex has created a broad and diversified portfolio of various assets, adding the next generation and new FDA biopharmaceutical products (Pfenex’s flagship product is injectable teriparatide (teriparatide of the former (terily pf708 and Bonsity ™), a healing candidate equivalent to Forteo® (injectable teriparatide). Injectable teriparatide has been announced in the United States for, among other things, osteoporosis therapy in some patients at risk of fracture, and marketing authorization programs are ending in other jurisdictions. Pfenex expands service station haematological oncology products in collaboration with Jazz Pharmaceuticals, adding PF743, a recombinant asparagina of Erwinia and PF745, a recombinant, recombinant half-life Erwinia asparaginae. anatoxin for use in prophylactic and curative vaccines cinemas
Pfenex investors and others deserve to note that Pfenex advertises critical Pfenex data to the public through media, adding its website (https://www.pfenex.com/), its investor relations website (https: // pfenex. investorroom .com /), press releases, presentations to the SEC, public conference calls, Twitter corporate account (https://twitter.com/pfenex), Facebok page (https://www.facebok.com/Pfenex-Inc-105908276167776/ timeline /) and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) to enclose the public a broad and non-exclusive fact-based disemicountry and comply with its obligations disclosed under the FD Regulations. Pfenex encourages its investors and others to monitor and review the facts that Pfenex makes public in those places, as this wisdom could be a concept about critical data. Note that this list may be counter-sensitive from time to time.
Compa Contact: [email protected]